S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
The gold catalyst we’ve waited for (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
The gold catalyst we’ve waited for (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
The gold catalyst we’ve waited for (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
The gold catalyst we’ve waited for (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
The gold catalyst we’ve waited for (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
The gold catalyst we’ve waited for (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
The gold catalyst we’ve waited for (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
The gold catalyst we’ve waited for (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
The gold catalyst we’ve waited for (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
The gold catalyst we’ve waited for (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
The gold catalyst we’ve waited for (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
The gold catalyst we’ve waited for (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
NASDAQ:MEDP

Medpace - MEDP Competitors

$181.52
-1.74 (-0.95%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$179.49
$182.92
50-Day Range
$174.31
$239.52
52-Week Range
$126.94
$241.48
Volume
264,480 shs
Average Volume
390,139 shs
Market Capitalization
$5.64 billion
P/E Ratio
24.80
Dividend Yield
N/A
Price Target
$235.50

MEDP vs. SYNH, CRL, INCY, ICLR, OGN, ROIV, BLCO, TXG, OPCH, and LNTH

Should you be buying Medpace stock or one of its competitors? The main competitors of Medpace include Syneos Health (SYNH), Charles River Laboratories International (CRL), Incyte (INCY), ICON Public (ICLR), Organon & Co. (OGN), Roivant Sciences (ROIV), Bausch + Lomb (BLCO), 10x Genomics (TXG), Option Care Health (OPCH), and Lantheus (LNTH). These companies are all part of the "medical" sector.

Medpace vs.

Syneos Health (NASDAQ:SYNH) and Medpace (NASDAQ:MEDP) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.

Syneos Health presently has a consensus price target of $54.00, indicating a potential upside of 57.30%. Medpace has a consensus price target of $235.50, indicating a potential upside of 29.74%. Given Syneos Health's higher possible upside, equities research analysts clearly believe Syneos Health is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syneos Health
2 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Medpace
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

93.5% of Syneos Health shares are owned by institutional investors. Comparatively, 82.5% of Medpace shares are owned by institutional investors. 0.3% of Syneos Health shares are owned by insiders. Comparatively, 20.6% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Syneos Health had 1 more articles in the media than Medpace. MarketBeat recorded 9 mentions for Syneos Health and 8 mentions for Medpace. Syneos Health's average media sentiment score of 1.08 beat Medpace's score of 0.39 indicating that Syneos Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Syneos Health
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Syneos Health has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Syneos Health has higher revenue and earnings than Medpace. Syneos Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syneos Health$5.39 billion0.66$266.50 million$2.5713.36
Medpace$1.46 billion3.86$245.37 million$7.3224.80

Syneos Health received 227 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 68.89% of users gave Syneos Health an outperform vote while only 64.39% of users gave Medpace an outperform vote.

CompanyUnderperformOutperform
Syneos HealthOutperform Votes
547
68.89%
Underperform Votes
247
31.11%
MedpaceOutperform Votes
320
64.39%
Underperform Votes
177
35.61%

Medpace has a net margin of 16.81% compared to Syneos Health's net margin of 4.94%. Medpace's return on equity of 60.42% beat Syneos Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Syneos Health 4.94% 13.19% 5.40%
Medpace 16.81% 60.42% 18.38%

Summary

Syneos Health beats Medpace on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MEDP vs. The Competition

MetricMedpaceCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$5.69B$3.79B$4.35B$5.82B
Dividend YieldN/A1.15%2.42%4.51%
P/E Ratio24.8012.76110.6914.21
Price / Sales3.8610,157.223,449.7256.89
Price / Cash21.1816.0719.7222.50
Price / Book14.6225.814.515.04
Net Income$245.37M$84.68M$115.12M$191.41M
7 Day Performance-1.64%-2.67%-1.78%-0.97%
1 Month Performance-6.38%-13.29%-7.77%-6.42%
1 Year Performance13.59%-38.10%-14.52%-17.45%

Medpace Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYNH
Syneos Health
2.9775 of 5 stars
$33.84
-3.4%
$54.00
+59.6%
-56.9%$3.49B$5.39B13.1729,395Short Interest ↓
Positive News
CRL
Charles River Laboratories International
3.2181 of 5 stars
$196.29
-1.2%
$270.83
+38.0%
-32.1%$10.01B$3.98B20.7321,400Analyst Report
INCY
Incyte
3.1049 of 5 stars
$72.26
-1.7%
$87.54
+21.1%
-10.9%$16.11B$3.39B47.542,324
ICLR
ICON Public
2.7991 of 5 stars
$208.63
-2.2%
$266.70
+27.8%
-12.9%$17.05B$7.74B34.0341,100
OGN
Organon & Co.
3.2141 of 5 stars
$21.85
-2.4%
$31.20
+42.8%
-36.8%$5.56B$6.17B6.0910,000
ROIV
Roivant Sciences
2.1851 of 5 stars
$7.27
-4.8%
$12.50
+71.9%
+53.8%$5.51B$55.29M-4.08620News Coverage
BLCO
Bausch + Lomb
2.3773 of 5 stars
$16.00
-2.6%
$21.54
+34.6%
N/A$5.60B$3.77B800.4012,900Short Interest ↓
TXG
10x Genomics
1.6101 of 5 stars
$48.76
-2.7%
$52.00
+6.6%
-30.5%$5.62B$516.41M-33.171,239
OPCH
Option Care Health
2.9088 of 5 stars
$31.06
-2.6%
$40.50
+30.4%
+11.7%$5.65B$3.94B37.428,058Positive News
LNTH
Lantheus
2.5945 of 5 stars
$80.47
-2.9%
$107.33
+33.4%
+53.4%$5.43B$935.06M236.68612Short Interest ↓
This page (NASDAQ:MEDP) was last updated on 3/29/2023 by MarketBeat.com Staff